Urinary Matrix Metalloproteinase-7 and Prediction of AKI Progression Post Cardiac Surgery
Table 1
Preoperative characteristics of patients with and without AKI progressiona.
Variables
AKI progression
Yes ()
No ()
Age (y)
0.42
Male, (%)
20 (71.4)
44 (47.3)
0.03
Diabetes, (%)
2 (7.1)
7 (7.5)
0.99
Hypertension, (%)
8 (28.6)
22 (23.7)
0.62
Congestive heart failure, (%)
10 (35.7)
50 (53.8)
0.13
Preoperative NYHA class III or IV
5 (17.9)
21 (22.6)
0.78
Preoperative creatinine (μmol/L)
<0.001
Preoperative eGFR (mL/min/1.73 m2)b
0.02
Preoperative medication, (%)
RAS inhibitors
12 (42.9)
23 (24.7)
0.09
Diuretics
25 (89.3)
89 (95.7)
0.35
Operative variables
CABG alone, (%)
1 (3.5)
2 (2.1)
0.55
Valve alone, (%)
20 (71.4)
66 (70.9)
0.99
CABG and valve surgery, (%)
2 (7.1)
5 (5.3)
0.66
CPB time (min)
0.006
Cross clamp time (min)
0.59
aAKI progression is defined as worsening of the AKI stage (stage 1 to either stage 2 or stage 3 or from stage 2 to stage 3). bCalculated by CKD-Epidemiology Collaboration equation 2009. Abbreviation: NYHA: New York Heart Association; eGFR: estimated glomerular filtration rate; RAS: renin-angiotensin system; CABG: coronary artery bypass grafting; CPB: cardiopulmonary bypass.
